Search Results 501-510 of 17402 for alopecia
All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5) grade =< 1 (except alopecia) at the time of ...
... alopecia not requiring systemic treatment, conditions not expected to recur in the absence of an external trigger. Patients with a history of organ ...
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or ...
o Subjects with type I diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders (such as vitiligo,psoriasis or alopecia) not ...
... alopecia or peripheral neuropathy can also be included; Palliative radiation to < 10% of bone marrow is permissible if completed within one week of ...
... alopecia) of any prior therapy for their malignancies. In Phase Ib patients must have no peripheral sensory neuropathy > Grade 1; Women of childbearing ...
Subjects with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not ...
The following are exceptions to this criterion: subjects with vitiligo or alopecia; subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable ...
With the exception of alopecia, and CTCAE Grade 2 neuropathy, any unresolved toxicities from prior therapy > Grade 1 at the time of starting study treatment.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.